Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Journal
The Lancet. Respiratory medicine
Journal Volume
9
Journal Issue
12
Pages
1396
Date Issued
2021
Author(s)
Liu, Ming-Che
Chen, Yen-Hsu
Lee, Wen-Sen
Hwang, Shinn-Jang
Cheng, Shu-Hsing
Ko, Wen-Chien
Hwang, Kao-Pin
Wang, Ning-Chi
Lee, Yu-Lin
Lin, Yi-Ling
Shih, Shin-Ru
Huang, Chung-Guei
Liao, Chun-Che
Liang, Jian-Jong
Chang, Chih-Shin
Chen, Charles
Lien, Chia En
Tai, I-Chen
Lin, Tzou-Yien
Abstract
MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20-49 years in a phase 1 trial, and provided a good cellular and humoral immune responses. We present the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan.
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article